Clinical and biological evolution of nephrotic syndrome patients and corticotherapy

• Published in: Le Mali medical Vol. 24; no. 1; p. 29
• Main Authors: Fongoro, S, Diallo, D, Maiga, M K
• Format: Journal Article
• Language: French
• Published: Mali 2009
• Subjects: Adolescent; Adult; Child; Child, Preschool; Female; Glucocorticoids - therapeutic use; Humans; Infant; Length of Stay; Male; Methylprednisolone - therapeutic use; Middle Aged; Nephrotic Syndrome - drug therapy; Prednisone - therapeutic use; Prospective Studies; Young Adult

This study was aimed to follow clinical and biological data of patients presenting a nephrotic syndrom apparently primitiv, devided in two groups. The study was prospectiv including 50 patients hospitalized from January 1999 to January 2001. The first group received prednison tablets according to their body weight, and the second group received firstly a bolus of methyl prednisone to the cumulative dose of 20mg/kg divided on 3 days; relayed by the 20mg/day of prednison tablets. The Chi2 test was estimated (p<or=0.05) The comparison of the age in the two groups was homogenous (p=0.37) and sex also (p=0.57). The ratio of these two parameters was 1.77 in favour of men. The nephrotic syndrom was pur by 38 patients (76%), and associated in 12 patients (24%). The evolution of body weight, dieresis, and proteinuria was significativ in the two groups (p<or=0.01). The blood pressure raised from 114/73 mmHg to 123/82 mmHg in the bolus group, and in the prednisone tablets group from 115/72 mmHg to 123/80 mmHg. The average hospitalisation was 5 weeks in first groups and 8 weeks in second before proteinuria disappeared in the urine. We concluted that methylprednisolon contributed to a faster normalisation of proteinuria and shorter hospitalisation time.